- Author(s):
- Organization(s):
Microsol Ltd University of Hertfordshire
In this opinion article, the authors discuss potential benefits of utilizing both empirical methods and in silico models for inhaled drug development. They also present two case studies, on modeling and the transition to low-GWP propellants, and modeling and predicting particle deposition.
From fluid dynamics and propellant evaporation to PK and regional lung deposition simulations, the authors believe in silico models can help reveal the complex interplay of formulation, device and patient physiology. These approaches could therefore assist in decreasing reliance on trial-and-error experimentation and support faster, more targeted development while reducing the risk of failure in later stages. When combined with experimental techniques and artificial intelligence, in silico models could help provide a more efficient, evidence-based route to designing inhaled therapies to be clinically effective as well as commercially and environmentally sustainable.
February 2026, Volume 20(1), pages 10-22